CBio's heat shock protein progressing for arthritis
This article was originally published in Scrip
CBio is around halfway to recruiting the 150 patients it needs for a new Phase IIa trial with a recombinant chaperonin 10 therapy for rheumatoid arthritis. The placebo-controlled study began in June at sites in Australia and New Zealand and is enrolling patients with active disease despite current therapy. The heat shock protein is thought to inhibit toll-like receptor signalling to prevent the over-expression of multiple pro-inflammatory cytokines, reducing immune cell activation and inflammation. The private Australian bioventure originally acquired rights from the University of Queensland and has also completed Phase IIa trials in psoriasis and multiple sclerosis.